Today's Daily Dose brings you news about Apellis Pharma's pipeline progress; licensing agreement between Knight Therapeutics and TherapeuticsMD; anticipated milestones of Progenics Pharma, and discontinuation of Shire's phase II NASH trial.
Original Article: APLS To Report Data In 2H, CUR Abuzz, Shire Discontinues NASH Trial